DUVYZAT Trademark

Trademark Overview


On Friday, April 1, 2022, a trademark application was filed for DUVYZAT with the United States Patent and Trademark Office. The USPTO has given the DUVYZAT trademark a serial number of 97342645. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, April 11, 2024. This trademark is owned by ITALFARMACO S.p.A.. The DUVYZAT trademark is filed in the Pharmaceutical Products category with the following description:

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
duvyzat

General Information


Serial Number97342645
Word MarkDUVYZAT
Filing DateFriday, April 1, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, April 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2023

Trademark Statements


Goods and ServicesBiochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders
Translation of Words in MarkThe wording "DUVYZAT" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 6, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameITALFARMACO S.p.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressMilano 20126
IT

Party NameITALFARMACO S.p.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressMilano 20126
IT

Trademark Events


Event DateEvent Description
Friday, April 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 11, 2024SOU EXTENSION 2 GRANTED
Thursday, April 11, 2024SOU EXTENSION 2 FILED
Thursday, April 11, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 23, 2023SOU EXTENSION 1 GRANTED
Tuesday, May 23, 2023SOU EXTENSION 1 FILED
Tuesday, May 23, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 2, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 7, 2023PUBLISHED FOR OPPOSITION
Wednesday, February 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 18, 2023ASSIGNED TO EXAMINER
Wednesday, April 6, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 5, 2022NEW APPLICATION ENTERED